Skip to content

Organization Program of DiabEtes INsulIN ManaGement: an open, multi-center, prospective, randomized, 16-week, controlled clinical study.

Organization Program of DiabEtes INsulIN ManaGement: an open, multi-center, prospective, randomized, 16-week, controlled clinical study.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001317
Enrollment
Unknown
Registered
2011-04-06
Start date
2011-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Structured education group:Subjects received structured diabetes education

Sponsors

Bayer Healthcare Company Ltd
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Written Informed consent obtained before any trial-related activities T2DM patients; 2. Age > 18 years old,male or female; 3. Continuous treated with two or more oral antidiabetic drugs (OADs) for the last 3 months,and the current HbA1c>7.5%; 4. Cooperative with structured management.

Exclusion criteria

Exclusion criteria: 1. Subject with type 1 diabetes; 2. Gestational diabetes mellitus and other specific types DM; 3. Those who are unwilling to sign in ICF; 4. Subject with repeated hypoglycemia; 5. Subject with BMI>30kg/m2; 6. Impaired liver function,defined as alanine aminotransferase (ALAT)>= 2.5 or alkaline phosphatase (ALP)>= 2 times upper referenced limit times upper normal limit; 7. Females of child bearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant or not using adequate contraceptive methods throughout the trial (adequate contraceptive measures as required by local law or practice); 8. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation; 9. Any other clinically significant condition or major systemic diseases, including serious coronary heart disease, cardiovascular disease, myocardial infarction within the past 12 month; sever neurology or psychology or psychiatric disease; serious infection; actively disseminated intravascular coagulation; 10. Malignant neoplastic disease (except carcinoma in situ); 11. Current addiction to alcohol or other addictive substances.

Design outcomes

Primary

MeasureTime frame
Investigate glycemic control as measured by HbA1c change;

Secondary

MeasureTime frame
Medication compliance;total daily insulin dose;7-points of glucose;Assess diabetes self-management ability by Diabetes Management Self-Efficacy (C-DMSES);body weight;Diabetes self-management skills Diabetes self-management skills Assess diabetes self-care ability by;The satisfaction degree of structured management;The incidence of Hypoglycemia;

Countries

China

Contacts

Public ContactXiaohui Guo, Linong Ji
guoxh@medmail.com.cn+86 10 83575662

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026